-
Mashup Score: 0Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial - 12 month(s) ago
AbstractAims. Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure with mildly reduced o
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2More ARNI Insights Fortify Role in ‘Below Normal’ LVEF: PARAGLIDE-HF - 12 month(s) ago
The trial, as well as pooled data with PARAGON-HF, should solidify a role for sacubitril/valsartan after worsening HF events.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
More #ARNI Insights Fortify Role in ‘Below Normal’ #LVEF: #PARAGLIDE-HF The trial, as well as pooled data with #PARAGON-HF, should solidify a role for sacubitril/valsartan after worsening HF events @TCTMD @ShelleyWood2 @mmamas1973 #HeartFailure2023 https://t.co/CcMUGMzrdt
-
-
Mashup Score: 1Video-Based AI Tool Estimates LVEF From Angiograms - 12 month(s) ago
An early demonstration of the novel artificial intelligence algorithm shows promise to estimate left ventricular ejection fraction without further invasive procedures, but not at the extremes of LVEF.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
A novel AI algorithm shows promise for estimating #LVEF from left coronary artery angiogram videos, new research shows. #ACCImaging member Dr. @alfonsowallermd shared his thoughts on the study with @Medscape: https://t.co/2zXHVkv3zy #cvImaging
-
-
Mashup Score: 2Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines - 1 year(s) ago
AbstractBackground and Aims. Anthracyclines can cause cancer therapy related cardiac dysfunction (CTRCD). We aimed to assess whether statins prevent decline in
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Primary prevention with atorvastatin during anthracycline therapy did not prevent cardiac dysfunction and myocardial tissue changes: SPARE-HF randomized trial https://t.co/9s2p9JSSq4 #echofirst #HF #LVEF #CMR #ESCYoung #EHJPharmacotherapy @FeliceGragnano @AgewallStefan https://t.co/7tKG4tdpcD
-
-
Mashup Score: 0AI model predicts LVEF during routine coronary angiograms - 1 year(s) ago
The video-based deep neural network showed potential for limiting invasive exams and improving patient care.
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#AI model predicts #LVEF during routine coronary angiograms @ucsfhealth @RobertAvramMD @ICMtl @HeartInstitute @GeoffTison #cardiology #cardiotwitter https://t.co/7zu3IfXGXW
-
-
Mashup Score: 0
Cardiac magnetic resonance (CMR)-based left ventricular end-systolic volume (LVES) volume assessment outperformed LV diameters in asymptomatic aortic regurgitation (AR) patients with preserved LV ejec
Categories: Cardiology News and Journals, Latest HeadlinesTweet-
#CMR-based LVES volume assessment outperformed LV diameters in asymptomatic AR patients with preserved #LVEF, a new #JACC study suggests. https://t.co/URjxBz2ZlR @CRT_meeting
-
-
Mashup Score: 7Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients - 1 year(s) ago
FDA approval means patients with heart failure can benefit from Farxiga regardless of left ventricular ejection fraction status AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA)…
Source: www.astrazeneca.comCategories: Cardiologists, Latest HeadlinesTweet-
.@US_FDA expands approval of #SGLT2i dapagliflozin to reduce CV death, HF hosp, & urgent HF visits to all adults w HF regardless of #LVEF based on #DELIVER. A 2nd major approval for #LVEF >40%. 👏🏾 to vision & leadership by @scottdsolomon @UoGHeartFailure https://t.co/lMoyi0PujH https://t.co/OqZ0yf9DOQ
-
-
Mashup Score: 1Should beta-blockers be recommended after myocardial infarction when left ventricular ejection fraction is normal? - 1 year(s) ago
For many years, clinical practice guidelines have recommended beta-blockers after myocardial infarction for all patients without a contraindication. In this issue of Heart, this recommendation is questioned by a propensity adjusted analysis from the SWEDEHEART registry which found no association between long-term beta-blocker use and mortality or major cardiovascular events in 43 618 patients…
Source: HeartCategories: Cardiologists, Latest HeadlinesTweet-
Do patients with a normal #LVEF benefit from long- term beta-blocker therapy after myocardial infarction? #CardioTwitter #BetaBlockers https://t.co/zYGc0ESKQs
-
-
Mashup Score: 1
A 57-year-old woman with known ischemic cardiomyopathy, heart failure with reduced ejection fraction (HFrEF), and left ventricular ejection fraction (LVEF) 25% is seen in the heart failure (HF) clinic. She has no acute concerns. Her blood pressure is 110/60 mm Hg, heart rate is 72 bpm, oxygen saturation is 97% on room air, and jugular venous pressure is 8 cm H2O. There is a regular rate and…
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet-
A 57 y/o woman with ischemic cardiomyopathy, #HFrEF & #LVEF is seen in the #HeartFailure clinic. She has no acute concerns. Fact or Fiction: The patient is "stable" and guideline-directed medical therapy should not be escalated at present. Vote: https://t.co/urklXr8Gt4 #ACCEd
-
-
Mashup Score: 5
Patients with heart failure (HF) represent a vulnerable population in need of optimal treatment and in-depth clinical care. In recent years, numerous randomized
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Prescribing trends of SGLT2-I across the spectrum of ejection fraction in HF patients: a 6-year analysis from a tertiary care center https://t.co/XHSWcDO8C8 @escardio #HF #LVEF #ESCYoung @AgewallStefan @FeliceGragnano #EHJPharmacotherapy https://t.co/hbBbPcgPFl
-
News from DELIVER trial: dapagliflozin's safety and efficacy across a wide range of background diuretic use! #dapaglifozin #DELIVER #heart failure #LVEF #safety #efficacy @ESC_Journals @escardio https://t.co/lyS4L8jMtB https://t.co/NOsgeIwPdS